338 results about "MicroRNA" patented technology

The invention relates to a preparation method of a microwave-assisted synthesized near-infrared electrochemical luminescence gold nanocluster and application of the gold nanocluster in miRNA (micro Ribonucleic Acid) detection. The preparation method comprises the following steps: under a stirring condition, adding a gold source and alkali into a Met solution to obtain a mixed solution, carrying out microwave irradiation reaction, and carrying out solid-liquid separation to obtain a Met-Au NCs solution; the preparation method comprises the following steps: activating a Met-Au NCs solution by using EDC and NHS, adding a DNA solution, mixing, and dialyzing to obtain a Met-Au NCs-DNA compound, namely the near-infrared electrochemical luminescence gold nanocluster. Compared with Au NCs prepared by a common mild method, the Met-stable Au NCs prepared by a microwave-assisted method has the advantage that the fluorescence and electrochemical luminescence efficiency at 835 nm is improved. The invention also provides a'signal closing 'ECL (electron cyclotron ligand) biosensor for high-sensitivity detection of the miRNA-107 (MicroRNA-107), and a method for detecting the miRNA-107 (MicroRNA-107). The sensor is simple to operate and good in repeatability, and has important scientific significance and application value for clinical early diagnosis of cancers.

The invention provides a nucleic acid aptamer and a screening method thereof, the aptamer is of an oligonucleotide DNA structure, the nucleotide sequence of the nucleic acid aptamer is the nucleotide sequence of any DNA fragment as shown in SEQ ID NO: 1-9, and the nucleic acid aptamer can specifically target cardiac muscle cells (CMs). According to the invention, a new strategy can be provided for clinical treatment of cardiovascular diseases, and meanwhile, bioactive molecules such as microRNA (miRNA), small interfering RNA (small interfering RNA, siRNA), lipidosome, microspheres, microcapsules and the like can be carried to be used as an intracellular drug delivery tool.

The present invention relates to miRNA biomarkers from milk, such as exosome-derived microRNAs from milk, as an indicator of welfare in bovine animals. In particular, the present invention relates to the identification of heat stress in bovine animals, allowing management measures to be proposed to improve productive animal welfare at individual or veterinary levels.

The present invention relates miRNA biomarkers and in particular to a combination of miRNA biomarkers, e.g. exosome-derived microRNA, as indicators of welfare in bovines. In particular, the present invention relates to the identification of heat stress in bovines allowing to propose management actions to improve productive animal welfare at the individual or the herd levels.

The present invention relates miRNA biomarkers from milk. e.g. exosome-derived microRNA from milk, as indicators of welfare in bovines. In particular, the present invention relates to the identification of heat stress in bovines allowing to propose management actions to improve productive animal welfare at the individual or the herd levels.

The invention relates to the technical field of medicine preparation, in particular to application of a microRNA244-5P inhibitor in preparation of a product for treating sepsis cardiomyopathy. According to the application of the microRNA 244-5P inhibitor in the preparation of the product for treating the sepsis cardiomyopathy, the sequence of the microRNA 244-5P inhibitor is shown as Seq. ID No. 1, and the microRNA 244-5P inhibitor can be applied to the preparation of the product for treating the sepsis cardiomyopathy. The provided microRNA 244-5P inhibitor lays a precise foundation for targeted treatment of sepsis cardiomyopathy. The inhibitor can specifically recognize and act on related targets, accurately intervene the pathological process of sepsis cardiomyopathy, has more stable structure and activity, can ensure that the inhibition effect can be continuously and efficiently played when a treatment product is prepared, provides a clear material basis and a technical basis for research, development, production and quality control of subsequent products, and has a wide application prospect. The pertinence and the effectiveness of treatment are greatly improved.

The invention provides oligonucleotide and / or oligonucleotide analogue molecules that are antagonists of a microRNA, preferably antagonists of human microRNAs hsa-miR-23b-3p and hsa-miR-218-5p, that comprise a mixture of phosphorothioate and phosphodiester linkages, and that are conjugated to at least one oleic acid molecule. Inhibiting these microRNAs allows to increase the endogenous levels of the corresponding proteins MBNL1 and / or MBNL2. The present invention further provides compositions comprising said oligonucleotides and / or oligonucleotide analogue molecules and their uses for the treatment and prevention of DM in a subject in need thereof.

The invention discloses a method for screening an active matter for protecting skin cell telomeres, and relates to the technical field of biotechnology and cosmetic development, and the method is technically characterized by comprising the following steps: a) providing stem cells derived from an exosome which carries at least one microRNA for regulating and controlling a telomere protection factor CTC1; b) acting a candidate active matter on the stem cells, and separating to obtain a treated exosome; the technical effects are as follows: the combination of miR-150-5p and miR-181c is delivered through the exosome, the dual-miRNA coordinated regulation is realized, the limitation of the traditional single-target detection is broken through, the CD63 / CD81 protein on the membrane surface of the exosome can be specifically combined with the skin cell membrane, and the Franz diffusion experiment verifies that the micro-fluidic chip integrates the collagen scaffold and the dynamic shear force.

The invention discloses a method for improving the application efficiency of frozen semen of sheep, and relates to the field of animal reproduction and breeding science, and the method comprises the following steps: collecting semen, freezing half of the semen, then respectively carrying out exosome extraction and identification experiments, then carrying out pandorah sequencing on small non-coding RNA (Ribonucleic Acid), and finally obtaining the application efficiency of the frozen semen of the sheep. The small non-coding RNA in fresh semen and frozen semen is qualitatively and quantitatively analyzed, differential expression microRNAs are screened out, corresponding target genes and signal channels are analyzed, and the small non-coding RNA and the signal channels related to semen cryopreservation are screened out. Finally, the differentially expressed small non-coding RNAs are added into frozen semen in a manner of in-vitro chemical synthesis and the like, or are added in an auxiliary manner during in-vitro artificial insemination, or are delivered through lipidosome, so that the phenotype of an embryo after insemination is influenced, the conception rate of in-vitro artificial insemination is increased, the problem in practical production is favorably solved, and the economic benefit is increased. And economic values are created for enterprises.

The invention discloses application of a PdePin1At protein and a coding gene thereof in regulation and control of a plant tree form. According to the invention, a transgenic poplar with reduced PdePin1At gene expression quantity is constructed by using a microRNA interference technology, and experiments prove that compared with a wild poplar, the leaf area, the leaf width, the leaf length, the branch included angle, the petiole length and the phyllotactic angle of the transgenic poplar are reduced, and the number of leaves / stem nodes is increased. The method is of great significance to molecular mechanism and theoretical research of regulating and controlling poplar tree forms, leaf shapes and quantity, branch angles and phyllotaxis, and is of great guiding significance to directional cultivation of trees with tree forms meeting actual production requirements. Under the condition that the plant height is not changed, the number of leaves of newborn organs can be increased, so that the number of photosynthetic organs is increased; and by changing the included angle of the branches, sunshine shielding can be reduced during close planting of the forest trees. Therefore, the method also has important guiding significance on agricultural production.

The purpose of the present invention is to provide a novel method for increasing the number of newly generated neurons in the adult brain, and to provide a polynucleotide, a vector, and a pharmaceutical composition for use in the method. The present invention provides: a polynucleotide characterized by including (A) the nucleic acid sequence of the Plagl2 gene, (B) an miR-shRNA (microRNA adapted short hairpin RNA) nucleic acid sequence for the Dyrk1a gene, and (C) a promoter sequence operatively connected to the nucleic acid sequences; a vector including the polynucleotide; and a pharmaceutical composition including the polynucleotide and the vector.

The invention relates to an intramolecular strand displacement reaction-based microRNA detection method and kit, and the kit is characterized in that the kit comprises four single-stranded sequences forming a DNA tetrahedron, a probe S and DNA polymerase; a probe T structure is designed at the top end of the DNA tetrahedron, and the probe T is used for capture of the probe S and intramolecular strand displacement reaction triggered by microRNA to be detected. The DNA tetrahedral structure is utilized to enhance the probe fixing efficiency and stability, and the detection sensitivity is improved; signal amplification is realized through intramolecular strand displacement reaction, and the detection limit is as low as 5 * 10 <-17 > mol / L; good selectivity is achieved, and single-base mismatch sequences can be distinguished; the kit has good performance in serum samples and has practical application potential.

The present invention relates to a formulation comprising an oligonucleotide drug which is an antagonist of microRNA-21 as an active agent for administration to a human subject in need thereof by inhalation.

The invention relates to application of a mir-331-3p inhibitor in preparation of a medicine for inhibiting malaria mosquito transmission, and belongs to the technical field of biological medicine. Aiming at the technical problems that the existing anti-malarial drug mainly acts on the later stage of plasmodium development and is lack of an effective propagation blocker, the invention provides the miR-331-3p inhibitor which is used for blocking the formation of plasmodium oocysts by inhibiting the interaction between microRNA and a mosquito target gene spetzle. Experiments show that the inhibitor can reduce the mosquito infection rate by about 50%, and has the characteristics of high targeting property, simplicity in operation and the like. The invention provides a novel drug development target for blocking malaria transmission, can effectively supplement the prevention and control blind area of the existing anti-malarial drug, and has important application value in the field of mosquito-borne infectious disease control.

Disclosed are compositions, methods, and kits for modifying DNA within cells as well as compositions and methods for modifying gene expression in a cell. In particular, the invention generally relates to compositions, methods, and kits for DNA editing using single-stranded DNA. Compositions and methods for modifying gene expression using artificial microRNAs (amiRNA) are also contemplated.

The application belongs to the technical field of biomedical engineering, and specifically discloses a nano gene composition for treating brain glioma and a preparation method thereof, which is synthesized from bovine serum albumin loaded manganese dioxide particles, PLGA, DSPE-PEG3000 and DSPE-PEG-Angiopep2 as raw materials; the average particle size of the nano gene composition is 122.18±31.3 nm. The application also discloses a preparation method of the nano gene composition. The nano gene composition provided by the application encapsulates miRNA-138 in PLGA to avoid the degradation of miRNA-138 by RNA enzymes in the body, and simultaneously utilizes the targeting property of Angiopep2 to target the delivery of the nano gene composition to tumor tissues, to deliver microRNA into the brain while reducing tumor hypoxia and increasing the sensitivity of cells to X-ray irradiation, so as to realize multidirectional comprehensive treatment of glioblastoma.

The invention relates to the use of a microRNA or a set of microRNAs in the in vitro differential diagnosis of forms of primary aldosteronism, wherein the microRNA is at least one microRNA selected from the following or wherein the set of microRNAs comprises at least two microRNAs selected from the following: hsa-miR-146a-5p, hsa-miR-361-5p, hsa-miR-24-3p, hsa-miR-130b-3p, hsa-miR-99b-5p, hsa-miR-151a-3p, hsa-miR-199a-3p, hsa-miR-128-3p and hsa-miR-28-3p. Preferably, the forms of primary aldosteronism are unilateral and bilateral forms, preferably unilateral aldosterone-producing adenoma (APA) and bilateral adrenal hyperplasia (BAH). The invention also relates to a method for the in vitro differential diagnosis of forms of primary aldosteronism in a subject.

The present invention provides nucleic acid molecules for modulating the level or amount of mRNA of FGFR4. In particular, the present invention provides delivery of a primary microRNA to form a precursor after in vivo processing, as well as a microRNA for in vivo inhibition of expression of mRNA of FGFR4. The invention also provides a delivery system of the nucleic acid molecule, comprising a carrier, an exosome and a cell, and a pharmaceutical composition containing the same. The invention also provides the use of the nucleic acid molecule and delivery system in disease treatment and drug preparation, in particular methods and drugs for cancer.

This invention belongs to the field of immunoassay and biosensing technology, and discloses a method for preparing a ratiometric ECL biosensor based on Eu / Tb-Lu MOGs. Using Eu / Tb-Lu MOGs as the luminescent material and H3-tctpy and luminol as ligands, a single-luminescent material with dual ECL emission is synthesized. Lanthanide ions provide the cathode ECL emission, enhanced by the antenna effect and Tb→Eu energy transfer; the anode emits light from luminol using dissolved oxygen in water, requiring only the addition of K2S2O8 as a single co-reactant, resulting in fewer side reactions and a stable signal. The dual-potential ratiometric sensing utilizes the dual ECL signal for self-calibration, improving anti-interference and reliability; the single-luminescent dual-potential system achieves synchronous anode / cathode luminescence, simplifying the system and improving detection accuracy. By detecting changes in the ECL signal of different concentrations of analytes, the detection of microRNA-126 is achieved.

The invention is directed to a miRNA with a RNA sequence comprising or consisting of hsa-miR-4784 with SEQ ID NO: 6, or a member of the miR-4784 family, or a primary transcript thereof, a precursor thereof, a mimic thereof or a combination for use as a medicament, preferably for use in treatment of a cardiac disease associated with loss of cardiac myocytes.

The invention discloses an epigenetics method for improving the cryopreservation efficiency of sheep semen. The method comprises the following steps: extracting seminal fluid of Donflilien and Hu sheep hybrid F1-generation sheep, dividing the seminal fluid into a fresh group and a frozen group, carrying out somatic cell removal and small non-coding RNA extraction, screening out differentially expressed microRNAs by utilizing a Pandorah sequencing technology, analyzing a target gene and a signal channel of the microRNAs, and determining the seminal fluid of the Donflilien and Hu sheep hybrid F1-generation sheep. The small non-coding RNA related to sperm cryopreservation is found to mainly relate to key biological processes such as oxidative stress response and cell surface receptor signal channels. The screened differentially expressed small non-coding RNA is added into the frozen semen through methods such as in vitro chemical synthesis, so that the artificial fertilization conception rate of the frozen semen is remarkably increased.

A method of assessing expression profiles of miRNA markers using predictive classification models to distinguish between non-diseased and diseased mitral valve disease, non-diseased and diseased DCM, non-diseased and diseased HCM. Additionally, an assessment of the same method is provided to discriminate pre-clinical from clinical MMVD or DCM patients. Also provided is a method of differentially diagnosing MMVD patients from DCM patients or from healthy controls.

The present application describes miRNAs in the diagnosis and treatment of small fiber neuropathy (SFN).

The invention relates to novel oligonucleotides and their use in inhibiting or reducing senescence. The oligonucleotides target specific sequences in the 3' untranslated region (UTR) of heterogeneous nuclear ribonucleoprotein D (HNRNPD) mRNA and blocks one or more inhibitory microRNA (miRNA) binding sites. This promotes the physiologically regulated expression of HNRNPD and reduces senescence.

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.

This invention discloses a microRNA-responsive 1,2-dioxane-based chemiluminescent compound, its dual-probe system, kit, synthesis method, and applications. The compound's core is an o-acrylate-substituted phenoxyadamantane-1,2-dioxane, with the phenolic hydroxyl group protected by an azide benzyl group. The two-component probe system constructed based on this compound comprises an azide-modified first probe and a phosphine-modified second probe, each complementary to different segments of the target microRNA. Hybridization brings the two probes closer, triggering a Staudinger reaction to remove the protecting group and activate the chemiluminescent signal. This probe system requires no enzyme amplification or nucleic acid extraction, achieves a detection limit of 1.37 fM, and a signal-to-noise ratio as high as 157-fold. It can be successfully used for real-time imaging of endogenous microRNA-21 in live cells, showing broad application prospects in early tumor screening, auxiliary diagnosis, and prognostic assessment.

Applicants have discovered differential expression and activity of various miRNAs in neurodegenerative diseases. These miRNAs can serve as therapeutic targets for prevention and treatment of neurodegenerative diseases. Accordingly, embodiments of the invention include formulations and methods for treating neurodegenerative diseases such as dementia and Alzheimer's disease. The formulations and methods can include five microRNAs and two small molecule therapeutics. In aspects, the miRNAs are MIR-145-3p, let-7c-3p, MIR-383-5p, MIR-548aj-3p and MIR-548x-3p. In aspects, the small molecule therapeutics are GATC-49, fucosterol and fucoidan. In aspects, the compounds work synergistically with one another.

The application discloses application of microRNA-32-5p in preparation of a medicine for preventing and treating osteoporosis, and a medicine composition taking microRNA-32-5p as an active ingredient. It is proved through experiments that knocking out the microRNA-32-5p gene significantly aggravates osteoporosis induced by estrogen deficiency; the microRNA-32-5p plays a bone protection role by promoting osteogenic differentiation of bone marrow mesenchymal stem cells. Therefore, the microRNA-32-5p can be applied to prevention and treatment of osteoporosis as a microRNA medicine.

Methods of diagnosing, monitoring, or treating gastric cancer (e.g., early gastric cancer) in a patient are accomplished by detecting the expression levels of RNA biomarkers (e.g., microRNA biomarkers) in a biological sample. Such RNA biomarkers include, for example, miR-21-3p, miR-21-5p, miR-215-5p, miR-335-3p, miR-27a-3p, miR-95-3p, miR-181b-5p, miR- 431-5p, miR-1246. miR-192-3p. miR-196a-5p, miR-183-5p, and miR-135b-5p. The RNA biomarkers can be cell-free miRNA, exosomal miRNA, or a combination thereof, such as cell-free miR-21-3p, cell-free miR-21-5p, cell-free miR-215-5p, cell-free miR-335-3p, cell-free miR- 27a-3p, cell-free miR-95-3p, cell-free miR-181b-5p, cell-free miR-431-5p, exosomal miR-21- 3p, exosomal miR-21-5p, exosomal miR-1246, exosomal miR-192-3p, exosomal miR-215-5p, exosomal miR-27a-3p, exosomal miR-95-3p, exosomal miR-196a-5p, exosomal miR-183-5p, and exosomal miR-135b-5p.